Back to School: How biopharma can reboot drug development. Access exclusive analysis here

What's driving spate of spin-offs

What's driving spate of spin-offs

Even though biotechnology companies are themselves young, they frequently spawn new companies. With three new ones announced in the past week - Apoptosis Technology Inc. by ImmunoGen Inc., CollOptics Inc. by Collagen Corp., and Vaxcel Inc. by CytRx Corp. - BioCentury asked several managers what goes into the strategic decision to start a company versus keeping a project in-house.

The key themes that emerged were increased upside for the parties involved in the new company and reduced costs for the parent company. More specifically, forming a new company makes it possible to provide a new team with equity

Read the full 1032 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE